Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
暂无分享,去创建一个
Francesmary Modugno | Honglin Song | Danielle Shadforth | Malcolm C Pike | Georgia Chenevix-Trench | Jolanta Lissowska | Paul D P Pharoah | Fergus J Couch | Ellen L Goode | Montserrat Garcia-Closas | Douglas F Easton | David C Whiteman | Alice S Whittemore | Lydia Quaye | Thomas A Sellers | Valerie McGuire | Edwin S Iversen | Jeffrey R Marks | Ian Jacobs | A. Whittemore | M. Pike | T. Sellers | F. Couch | B. Ponder | M. García-Closas | E. Goode | A. Berchuck | E. Iversen | D. Easton | P. Pharoah | I. Jacobs | G. Chenevix-Trench | L. Brinton | J. Lissowska | B. Pepłońska | J. Beesley | J. Cunningham | M. Goodman | A. Wu | J. Tyrer | S. Gayther | L. Quaye | R. Ness | D. Whiteman | R. Dicioccio | J. Schildkraut | K. Moysich | F. Modugno | A. Green | C. Pearce | M. Carney | V. McGuire | Honglin Song | P. Webb | G. Lurie | R. Edwards | E. Høgdall | C. Høgdall | S. Ramus | Jan Blaeker | Andrew Berchuck | Marc T Goodman | Julie M Cunningham | Beata Peplonska | Bruce A J Ponder | Penelope M Webb | Susan J Ramus | Estrid Hogdall | Simon A Gayther | Jonathan Beesley | Jonathan Tyrer | Anna H Wu | Kirsten B Moysich | Galina Lurie | Louise Brinton | Michael E Carney | Claus Hogdall | Roberta B Ness | Robert P Edwards | Joellen Schildkraut | Susan Krüger Kjaer | Jan Blaeker | Richard DiCioccio | Adele C Green | C Leigh Pearce | J. Marks | S. K. Kjaer | Danielle Shadforth | A. Green
[1] E. Garrett,et al. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. , 1995, Cancer research.
[2] A. Whittemore,et al. Common variants in RB1 gene and risk of invasive ovarian cancer. , 2006, Cancer research.
[3] D. Gertig,et al. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[4] D. Duggan,et al. Recent developments in genomewide association scans: a workshop summary and review. , 2005, American journal of human genetics.
[5] A. Spurdle,et al. CYP17 promotor polymorphism and ovarian cancer risk , 2000, International journal of cancer.
[6] Malcolm C Pike,et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. , 2005, Journal of the National Cancer Institute.
[7] L. Kolonel,et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[8] A. Spurdle,et al. BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk , 2003, International journal of cancer.
[9] A. Spurdle,et al. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. , 2001, Carcinogenesis.
[10] R. Berkowitz,et al. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. , 2002, Cancer research.
[11] A. Berchuck,et al. Progesterone receptor gene polymorphism and risk for breast and ovarian cancer. , 1998, British Journal of Cancer.
[12] A. Whittemore,et al. Common variants in mismatch repair genes and risk of invasive ovarian cancer. , 2006, Carcinogenesis.
[13] A. Sood,et al. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. , 1997, Cancer gene therapy.
[14] R. Nelson,et al. The HRAS1 minisatellite locus and risk of ovarian cancer. , 2000, Cancer research.
[15] A. Spurdle,et al. The prohibitin 3' untranslated region polymorphism is not associated with risk of ovarian cancer. , 2003, Gynecologic oncology.
[16] J. Lancaster,et al. p53 polymorphism in ovarian and bladder cancer , 1995, The Lancet.
[17] Funk Jo,et al. Cancer cell cycle control. , 1999 .
[18] G. Giles,et al. Androgen receptor exon 1 cag repeat length and risk of ovarian cancer , 2000, International journal of cancer.
[19] A. Whittemore,et al. STK15 polymorphisms and association with risk of invasive ovarian cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[20] I. Nagata,et al. Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer , 2002, International journal of cancer.
[21] G. Abecasis,et al. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.
[22] A. Whittemore,et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk , 2005, International journal of cancer.
[23] Christopher A. Haiman,et al. Choosing Haplotype-Tagging SNPS Based on Unphased Genotype Data Using a Preliminary Sample of Unrelated Subjects with an Example from the Multiethnic Cohort Study , 2003, Human Heredity.
[24] A. Kibel,et al. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. , 2003, Cancer research.
[25] N. Umesaki,et al. The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] Douglas F. Easton,et al. Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.
[27] S. Chow,et al. Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer , 2004, International Journal of Gynecologic Cancer.
[28] D. Easton,et al. Risk prediction models for familial breast cancer. , 2006, Future oncology.
[29] R. Vierkant,et al. Estrogen Bioactivation, Genetic Polymorphisms, and Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[30] Minoru Yoshida,et al. The Cytoplasmic Shuttling and Subsequent Degradation of p27Kip1 Mediated by Jab1/CSN5 and the COP9 Signalosome Complex* , 2002, The Journal of Biological Chemistry.
[31] K. Shigemasa,et al. Cyclin D1 Overexpression and p53 Mutation Status in Epithelial Ovarian Cancer , 1999, The Journal of the Society for Gynecologic Investigation: JSGI.
[32] N. Ragni,et al. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[34] Ralph Weissleder,et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Kreienberg,et al. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer , 1995, The Lancet.
[36] Frank Dudbridge. A note on permutation tests in multistage association scans. , 2006, American journal of human genetics.
[37] B. Ponder,et al. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. , 1999, American journal of human genetics.
[38] T. Löning,et al. p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper‐methylation or mutation in endometrioid and mucinous tumors , 1998, International journal of cancer.
[39] D. Levine,et al. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. , 2001, Cancer research.
[40] R. Weinberg,et al. Control of the cell cycle and apoptosis. , 1999, European journal of cancer.